In this episode, we spotlight Forum Discussion 5 from the AD/PD™ 2025 International Conference — “Novel Approaches to Accelerate Development of Biomarkers, Imaging, and Therapy of Alpha-Synuclein, LRRK2, and GBA Pathologies Linked to PD, LBD, and MSA.”

Moderated by Dr. Jamie Eberling (USA) and Dr. Ken Marek (USA), the discussion brought together leading experts: Prof. Fabrizio Stocchi (Italy), Prof. Amos Korczyn (Israel), Dr. Tomislav Babic (Austria), Dr. Maria Maccecchini (USA), Dr. Robert Drolet (USA), Dr. Jose-Alberto Palma (USA), and Dr. Tania Nikolcheva (Switzerland).

Key highlights include:

• The promise of digital biomarkers, including app-based approaches to monitor disease progression

• Advances and challenges in developing alpha-synuclein PET ligands and the importance of curated patient samples

• Precision medicine strategies targeting lysosomal, mitochondrial, and neuroinflammatory pathways

• The potential of GLP-1 receptor agonists and combination therapies for Parkinson’s and related disorders

• Progress toward patient stratification using genetic and biomarker profiles to improve outcomes

• Critical reflections on causation vs. correlation in biomarker science

• How Multiple System Atrophy (MSA) may serve as a model to accelerate therapy developmentThis episode is relevant for neuroscientists, clinicians, industry researchers, biotech developers, and anyone interested in advancing biomarker science, precision medicine, and therapeutic innovation in Parkinson’s disease, Lewy Body Dementia, and MSA.

This podcast was created using AI to provide a quick and insightful summary of an AD/PD™ 2025 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information.

The AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, took place on April 1-5, 2025, in Vienna Austria.

https://adpd.kenes.com/